Premium
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
Author(s) -
Khan Saad A.,
Ci Bo,
Xie Yang,
Gerber David E.,
Beg Muhammad S.,
Sherman Steven I.,
Cabanillas Maria E.,
Busaidy Naifa L.,
Burtness Barbara A.,
Heilmann Andreas M.,
Bailey Mark,
Ross Jeffrey S.,
Sher David J.,
Ali Siraj M.
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25634
Subject(s) - neuroblastoma ras viral oncogene homolog , hras , cdkn2a , kras , pten , anaplastic thyroid cancer , thyroid cancer , cancer research , cancer , biology , pdgfra , medicine , oncology , gene , genetics , bioinformatics , mutation , pi3k/akt/mtor pathway , apoptosis , gist , stromal cell
Anaplastic thyroid cancer (ATC) is a highly aggressive thyroid cancer. Those ATC with genomic alterations (GAs) in TSC2 , ALK , and BRAF may respond to targeted therapies. Methods Comprehensive genomic profiling on 90 ATC specimens identified base substitutions, short insertions and deletions, amplifications, copy number alterations, and genomic rearrangements in up to 315 cancer‐related genes and 28 genes commonly rearranged in cancer. Results Median patient age was 65 (range, 33‐86) years, 50 patients were male. There was a mean of 4.2 GA per case, range 1‐11. The most common GA were TP53 (66%), BRAF (34%), TERT (32%), CDKN2A (32%), and NRAS (26%). BRAF V600E and NRAS / HRAS/KRAS alteration were mutually exclusive. BRAF , CDKN2A , PIK3CA , and JAK2 were more frequent in patients >70 years of age; while myc , PTEN , and NRAS were more common in those ≤50 years. Conclusion ATC shows many GA with potential therapeutic significance and suggesting different molecular pathways can lead to ATC.